December 27, 2012
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice of Issuance of 1st Unsecured Convertible Bond with Stock Acquisition Rights and 29th Warrant by Third-Party Allotment

TOKYO, Japan, December 27, 2012 – SymBio Pharmaceuticals Limited (JASDAQ: 4582) today announced that a resolution was passed at the Company's Board of Directors Meeting held on December 27, 2012, to issue SymBio's first unsecured convertible bond with stock acquisition rights and the 29th warrant by third-party allotment.

1. Summary of Subscription

(1) The first unsecured convertible bond with stock acquisition rights

(1) Due date of payment	January 15, 2013
(2) Total number of stock acquisition rights	40
(3) Total issue price of convertible bond with stock acquisition rights	Issue price per convertible bond: 25 million JPY (100 yen per 100 yen par value) No cash payment required for issuance of convertible bond with stock acquisition rights
(4) Dilutive share amount of issuance	3,311,258 Shares
(5) Amount of Funding	1,000,000,000 JPY
(6) Conversion Price	302 JPY
(7) Method of subscription or Allotment	All convertible bond with stock acquisition rights are allocated to Whiz Healthcare PE Series 1 Investment Limited Liability Partnership by third-party allotment
(8) Interest rate	Bond does not bear interest
(9) Others(8) Interest rate	The preceding terms of subscription conditional upon notification of such terms coming into force in accordance with the Financial Instruments and Exchange ActBonds do not bear interest
(9) Others	The preceding terms of subscription conditional upon notification of such terms coming into force in accordance with the Financial Instruments and Exchange Act

(2) The 29th Warrant

(1) Date of allotment	January 15, 2013
(2) Total number of warrant	50 Warrants
(3) Total issue price	Total of 5,100,000 JPY (102,000 JPY per equity warrant)
(4) Dilutive share amount of issuance	1,326,250 Shares
(5) Amount of Funding	505,100,000 JPY (breakdown) Amount of Issuance 5,100,000 JPY Amount of Exercise 500,000,000 JPY
(6) Exercise Price	377 JPY
(7) Method of subscription or allotment	All of these warrants are allocated to Whiz Healthcare PE Series 1 Investment Limited Liability Partnership by third-party allotment.
(8) Others	The preceding items are conditional upon the notification of such items coming into force in accordance with the Financial Instruments and Exchange Act

(3) Profile of investor

i. Name of the fund: Whiz Healthcare PE Series 1 Investment Limited Liability Partnership
ii. Investment policy of the fund:
To invest in companies which develop pharmaceutical products based on scientific and technological innovation, as well as discoveries to protect and enhance human health.
iii. General partner:
The fund was established by Whiz Partners Inc., the general partner of the fund, in April, 2012. Whiz Partners is one of the few investment companies having longstanding experience and a successful track record in the life science field from the earliest days of the industry in Japan. Whiz Partners has invested in over 30 companies globally since it began to actively invest in the life sciences in 1999.
(For more information, please visit their website at http://www.whizp.com/e/index.html)
CSK-VC Technology Innovation Fund Limited Partnership, with Whiz Partners as its general partner, currently owns 84,000 shares of SymBio.

(4) Reasons for forming an investment partnership with Whiz Partners

i. Whiz Partners is familiar with SymBio's business strategy, robust pipeline and SE (search and evaluation)/development capabilities.
ii. Whiz Partners has in-depth knowledge and experience in the healthcare industry as well as a proven global investment track record in the industry
iii. Whiz Partners has earned a global reputation as a financially adept and independently owned investment company

2. Strategic implications and reasons for this financing

Since its establishment in March, 2005, SymBio has pursued new drug development with the underlying aim of addressing underserved medical needs in the oncology, hematology, and

autoimmune areas in Japan and other Asia Pacific markets. Outstanding execution capabilities have enabled SymBio to shorten time to market for TREAKISYM® (SyB L-0501, bendamustine hydrochloride), which required only five years from the signature of a license agreement with Astellas Deutschland GmbH to market approval for the treatment of refractory/relapsed low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL).

The short approval time of TREAKISYM® is validation of the effectiveness of SymBio's business model and its corporate strategy to in-license U.S and EU drug candidates, which have established proof of concept. This strategy has resulted in reduced development costs, compressed development timelines and shortened time to market. SymBio continues to conduct line expansion studies for additional indications for TREAKISYM®, such as frontline NHL to maximize the drug's therapeutic and market potential.

Building a pipeline with multiple drug candidates for underserved markets with orphan-like indications and lower competition will enable SymBio to achieve steady growth. As such, SymBio is also focused on other core products, such as rigosertib (iv and oral formulation), a unique patented multi-kinase inhibitor in-licensed from Onconova Therapeutics, Inc. ("Onconova") in July, 2011, for development and commercialization in Japan and Korea.

Onconova Therapeutics Inc. is currently conducting late-stage clinical trials with rigosertib in the U.S., EU and India for the treatment of MDS and solid tumors. A pivotal phase III trial for refractory/relapsed MDS is underway using the intravenous (iv) formulation of rigosertib. The U.S. FDA has granted orphan drug designation and a Special Protocol Assessment (SPA) for this rigosertib program. Additionally, the oral formulation of rigosertib is being developed for frontline MDS and other indications following the successful completion of phase I trials. In tandem with Onconova's clinical program, SymBio is conducting a phase I trial for the treatment of refractory/relapsed MDS using the iv formulation of rigosertib, with a phase I trial using the oral formulation planned to commence shortly..

In September, 2012, Onconova concluded a European licensing agreement for rigosertib with Baxter International Inc. Under the agreement, Onconova may receive up to $515 million in pre-commercial development and regulatory milestones for the MDS and pancreatic cancer indications, in addition to sales milestones and royalties. This partnership is expected to accelerate the development timeline of rigosertib in Japan and Korea through the use of overseas data by SymBio. Full development of rigosertib in MDS, and possibly other solid tumor indications, will require additional financing by SymBio.

In addition to TREAKISYM® and rigosertib programs, SymBio plans to use additional capital to in-license new drug candidates for development and commercialization. This additional capital is expected to augment the current and planned revenue streams associated with TREAKISYM®.

Both parties, SymBio and Whiz Partners, have assessed SymBio's future capital requirements and have agreed to this financing plan. Additionally, Whiz Partners has agreed to share its current network and resources to identify in-licensing opportunities, introduce partnerships and enhance investor relations activities when needed.

SymBio's Current Pipeline



Use of funds

Use of funds	Amount (millions of JPY)
SyB C-1101 (rigosertib, oral) for the treatment of frontline MDS	1,494
SyB L/C (rigosertib, iv & oral) for other indications (excluding frontline MDS)	
Costs associated with in-licensing new drug candidate (s)	

3. Major Shareholders and Shareholder Ratio after subscription

Before Subscription (as of December 26)		After Subscription	
Fuminori Yoshida	15.84%	Whiz Healthcare PE Series 1 Investment Limited Liability Partnership	19.51%
Cephalon, Inc. (Teva)	13.53%	Fuminori Yoshida	12.75%
JAFCO V2 Investment Limited	12.07%	Cephalon, Inc. (Teva)	10.89%

Co-Partnership			
Eisai Co., Ltd.	4.36%	JAFCO V2 Investment Limited Co-Partnership	9.71%
Waseda 1 Investment Limited Partner	3.58%	Eisai Co., Ltd.	3.51%
Fujimoto Corporation	3.29%	Waseda 1 Investment Limited Partner	2.88%
Waseda Global 1 Investment Limited Partner	2.61%	Fujimoto Corporation	2.65%
TNP on the Road Investment Limited Partner	1.33%	Waseda Global 1 Investment Limited Partner	2.10%
Daiichi Sankyo Co., Ltd.	1.05%	TNP on the Road Investment Limited Partner	1.07%

(Note)

1. Shareholder Ratio before subscription prepared based on the amount of shares in the shareholder registry as of September 30, 2012.
2. Shareholder Ratio after subscription is calculated using the amount of shares before subscription and adding the shares associated with the convertible bonds and related stock acquisition rights, as well as the 29th warrant.

4. Future prospects

The issuance of the convertible bond with stock acquisition rights and the 29th Warrant by third-party allotment will have no effect on business performance in FY2012. SymBio plans to announce its "Long Range Plan" promptly following the release of FY2012 Financial Results on February 14, 2013.